| [1] |
Forgacova N，Gazdarica J，Budis J，et al. Repurposing non-invasive prenatal testing data：Population study of single nucleotide variants associated with colorectal cancer and Lynch syndrome［J］. Oncol Lett，2021，22（5）：779.
|
| [2] |
Li X，Liu G，Wu W. Recent advances in Lynch syndrome［J］. Exp Hematol Oncol，2021，10（1）：37.
|
| [3] |
De Vos Tot Nederveen Cappel WH，Nagengast FM，Griffioen G，et al. Surveillance for hereditary nonpolyposis colorectal cancer：a long-term study on 114 families［J］. Dis Colon Rectum，2002，45（12）：1588-1594.
|
| [4] |
Boland PM，Yurgelun MB，Boland CR. Recent progress in Lynch syndrome and other familial colorectal cancer syndromes［J］. CA Cancer J Clin，2018，68（3）：217-231.
|
| [5] |
刘超，姬乐，白铁成. MSI状态与Ⅱ期、Ⅳ期结肠癌患者预后及其病理特征的相关性分析及思考［J/CD］. 中华普外科手术学杂志（电子版），2019，13（03）：283-286.
|
| [6] |
Wright JD，Silver ER，Tan SX，et al. Cost-effectiveness Analysis of Genotype-Specific Surveillance and Preventive Strategies for Gynecologic Cancers Among Women With Lynch Syndrome［J］. JAMA Netw Open，2021，4（9）：e2123616.
|
| [7] |
Dominguez-Valentin M，Crosbie EJ，Engel C，et al. Risk-reducing hysterectomy and bilateral salpingo-oophorectomy in female heterozygotes of pathogenic mismatch repair variants：a Prospective Lynch Syndrome Database report［J］. Genet Med，2021，23（4）：705-712.
|
| [8] |
Tougeron D，Mouillet G，Trouilloud I，et al. Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability：A Large Multicenter AGEO Study［J］. J Nati Cancer Inst，2016，108（7）：djv438.
|
| [9] |
Pietrantonio F，Miceli R，Raimondi A，et al. Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer［J］. J Clinical Oncol，2019，37（35）：3392-3400.
|
| [10] |
Han S，Chok AY，Peh DYY，et al. The distinct clinical trajectory，metastatic sites，and immunobiology of microsatellite-instability-high cancers［J］. Front Genet，2022，13：933475.
|
| [11] |
孙家琛，陈俊榕，赖明广. 进展期直肠癌新辅助放疗与化放疗联合TME随机对照试验的Meta分析［J/CD］. 中华普外科手术学杂志（电子版），2018，12（06）：485-489.
|
| [12] |
Baretti M，Le DT. DNA mismatch repair in cancer［J］. Pharmacol Ther，2018，189：45-62.
|
| [13] |
Vilar E，Scaltriti M，Balmaña J，et al. Microsatellite instability due to hMLH1 deficiency is associated with increased cytotoxicity to irinotecan in human colorectal cancer cell lines［J］. Br J Cancer，2008，99（10）：1607-1612.
|
| [14] |
Mas-Ponte D，Mccullough M，Supek F. Spectrum of DNA mismatch repair failures viewed through the lens of cancer genomics and implications for therapy［J］. Clin Sci（Lond），2022，136（5）：383-404.
|
| [15] |
Cercek A，Dos Santos Fernandes G，Roxburgh CS，et al. Mismatch Repair-Deficient Rectal Cancer and Resistance to Neoadjuvant Chemotherapy［J］. Clin Cancer Res，2020，26（13）：3271-3279.
|
| [16] |
Reijnen C，Küsters-Vandevelde HVN，Prinsen CF，et al. Mismatch repair deficiency as a predictive marker for response to adjuvant radiotherapy in endometrial cancer［J］. Gynecol Oncol，2019，154（1）：124-130.
|
| [17] |
Overman MJ，Lonardi S，Wong KYM，et al. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer［J］. J Clin Oncol，2018，36（8）：773-779.
|
| [18] |
Overman MJ，Mcdermott R，Leach JL，et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer（CheckMate 142）：an open-label，multicentre，phase 2 study［J］. Lancet Oncol，2017，18（9）：1182-1191.
|
| [19] |
Diaz LA，Shiu K-K，Kim T-W，et al. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer（KEYNOTE-177）：final analysis of a randomised，open-label，phase 3 study［J］. Lancet Oncol，2022，23（5）：659-670.
|
| [20] |
Lenz H-J，Van Cutsem E，Luisa Limon M，et al. First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer：The Phase II CheckMate 142 Study［J］. J Clin Oncol，2022，40（2）：161-170.
|
| [21] |
André T，Lonardi S，Wong KYM，et al. Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer：4-year follow-up from CheckMate 142［J］. Ann Oncol，2022，33（10）：1052-1060.
|
| [22] |
Winer A，Ghatalia P，Bubes N，et al. Dual Checkpoint Inhibition with Ipilimumab plus Nivolumab After Progression on Sequential PD-1/PDL-1 Inhibitors Pembrolizumab and Atezolizumab in a Patient with Lynch Syndrome，Metastatic Colon，and Localized Urothelial Cancer［J］. Oncologist，2019，24（11）：1416-1419.
|
| [23] |
Pastor DM，Schlom J. Immunology of Lynch Syndrome［J］. Curr Oncol Rep，2021，23（8）：96.
|
| [24] |
Ding L，Kim H-J，Wang Q，et al. PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer［J］. Cell Rep，2018，25（11）：2972-2980.
|
| [25] |
Deshpande M，Romanski PA，Rosenwaks Z，et al. Gynecological Cancers Caused by Deficient Mismatch Repair and Microsatellite Instability［J］. Cancers，2020，12（11）：3319.
|
| [26] |
Ferriss JS，Williams-Brown MY. Immunotherapy：Checkpoint Inhibitors in Lynch-Associated Gynecologic Cancers［J］. Curr Treat Options Oncol，2019，20（10）：75.
|
| [27] |
Hildebrand LA，Pierce CJ，Dennis M，et al. Artificial Intelligence for Histology-Based Detection of Microsatellite Instability and Prediction of Response to Immunotherapy in Colorectal Cancer［J］. Cancers，2021，13（3）：391.
|
| [28] |
Reyes-Uribe L，Wu W，Gelincik O，et al. Naproxen chemoprevention promotes immune activation in Lynch syndrome colorectal mucosa［J］. Gut，2021，70（3）：555-566.
|
| [29] |
Chau R，Dashti SG，Ait Ouakrim D，et al. Multivitamin，calcium and folic acid supplements and the risk of colorectal cancer in Lynch syndrome［J］. Int J Epidemiol，2016，45（3）：940-953.
|
| [30] |
Lu KH，Loose DS，Yates MS，et al. Prospective multicenter randomized intermediate biomarker study of oral contraceptive versus depo-provera for prevention of endometrial cancer in women with Lynch syndrome［J］. Cancer Prev Res（Phila），2013，6（8）：774-781.
|
| [31] |
Balint JP，Gabitzsch ES，Rice A，et al. Extended evaluation of a phase 1/2 trial on dosing，safety，immunogenicity，and overall survival after immunizations with an advanced-generation Ad5［E1-，E2b-］-CEA（6D）vaccine in late-stage colorectal cancer［J］. Cancer Immunol Immunother，2015，64（8）：977-987.
|
| [32] |
Kimura T，Mckolanis JR，Dzubinski LA，et al. MUC1 vaccine for individuals with advanced adenoma of the colon：a cancer immunoprevention feasibility study［J］. Cancer Prev Res（Phila），2013，6（1）：18-26.
|
| [33] |
Gebert J，Gelincik O，Oezcan-Wahlbrink M，et al. Recurrent Frameshift Neoantigen Vaccine Elicits Protective Immunity With Reduced Tumor Burden and Improved Overall Survival in a Lynch Syndrome Mouse Model［J］. Gastroenterology，2021，161（4）：1288-1302.e13.
|
| [34] |
Lanuza PM，Alonso MH，Hidalgo S，et al. Adoptive NK Cell Transfer as a Treatment in Colorectal Cancer Patients：Analyses of Tumour Cell Determinants Correlating With Efficacy and in Vivo［J］. Front Immunol，2022，13：890836.
|
| [35] |
Kloor M，Reuschenbach M，Pauligk C，et al. A Frameshift Peptide Neoantigen-Based Vaccine for Mismatch Repair-Deficient Cancers：A Phase I/IIa Clinical Trial［J］. Clin Cancer Rese，2020，26（17）：4503-4510.
|
| [36] |
Kloor M，Michel S，Buckowitz B，et al. Beta2-microglobulin mutations in microsatellite unstable colorectal tumors［J］. Int J Cancer，2007，121（2）：454-458.
|
| [37] |
Tikidzhieva A，Benner A，Michel S，et al. Microsatellite instability and Beta2-Microglobulin mutations as prognostic markers in colon cancer：results of the FOGT-4 trial［J］. Br J Cancer，2012，106（6）：1239-1245.
|
| [38] |
Zeytin HE，Patel AC，Rogers CJ，et al. Combination of a poxvirus-based vaccine with a cyclooxygenase-2 inhibitor（celecoxib）elicits antitumor immunity and long-term survival in CEA.Tg/MIN mice［J］. Cancer Res，2004，64（10）：3668-3678.
|
| [39] |
Massarelli E，William W，Johnson F，et al. Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer：A Phase 2 Clinical Trial［J］. JAMA Oncol，2019，5（1）：67-73.
|
| [40] |
Santiago-Sánchez GS，Hodge JW，Fabian KP. Tipping the scales：Immunotherapeutic strategies that disrupt immunosuppression and promote immune activation［J］. Front Immunol，2022，13：993624.
|
| [41] |
De Geyter C. Assisted reproductive technology：Impact on society and need for surveillance［J］. Best Pract Res Clin Endocrinol Metab，2019，33（1）：3-8.
|
| [42] |
Fesahat F，Montazeri F，Hoseini SM. Preimplantation genetic testing in assisted reproduction technology［J］. J Gynecol Obstet Hum Reprod，2020，49（5）：101723.
|
| [43] |
Daina G，Ramos L，Obradors A，et al. First successful double-factor PGD for Lynch syndrome：monogenic analysis and comprehensive aneuploidy screening［J］. Clin Genet，2013，84（1）：70-73.
|